Table 3

Secondary efficacy variables: changes in Brief Social Phobia Scale (BSPS), Fear of Negative Evaluations (FNE), Fear Questionnaire (FQ), Sheehan Disability Inventory (SDI), and the mental sub-scale of Short-Form—36 (SF—36) during treatment

Placebo (n=92) Sertraline and exposure therapy (n=98) Sertraline (n=95) Exposure therapy (n=93)
Mean change (s.e.) Mean change (s.e.) v. placebo P 95% CI Mean change (s.e.) v. placebo P 95% CI Mean change (s.e.) v. placebo P 95% CI
All scales patient-rated. Scale ranges: BSPS fear and avoidance sub-scales: 0-28; physiological: 0-16; FNE: 0-30; FQ: 0-40; SDI subscales: 0-10; SF-36: 0-100.
All calculations adjusted for baseline values and country. Bonferroni adjustment for multiple comparisons performed.
BSPS
Fear 14.19 (0.69) 16.42 (0.68) 2.23 0.132 -0.34 to 4.80 14.22 (0.67) 1.23 1.00 -1.33 to 3.78 15.54 (0.68) 1.34 1.00 -1.23 to 3.91
Avoidance 5.96 (0.60) 7.58 (0.59) 1.62 0.327 -0.61 to 3.85 6.54 (0.58) 0.58 1.00 -1.63 to 2.80 7.10 (0.58) 1.14 1.00 -1.08 to 3.35
Physiological 3.41 (0.34) 4.55 (0.33) 1.14 0.103 -0.12 to 2.40 3.92 (0.33) 0.52 1.00 -0.74 to 1.77 4.29 (0.33) 0.89 0.388 -0.38 to 2.15
FNE
Total score 4.85 (0.87) 6.96 (0.87) 2.11 0.534 -1.80 to 5.32 5.78 (0.85) 0.93 1.00 -2.32 to 4.18 4.88 (0.85) 0.03 1.00 -3.21 to 3.27
FQ
Total score 4.35 (0.87) 9.23 (0.88) 4.88 0.001 1.60 to 8.16 8.70 (0.87) 4.35 0.003 1.09 to 7.62 7.55 (0.86) 3.20 0.055 -0.08 to 6.44
SDI
Work 1.04 (0.29) 2.92 (0.29) 1.88 <0.001 0.80 to 2.96 2.26 (0.28) 1.23 0.015 0.16 to 2.30 2.42 (0.28) 1.38 0.004 0.80 to 2.96
Social life 1.63 (0.30) 3.60 (0.30) 1.97 <0.001 0.85 to 3.09 3.01 (0.30) 1.37 0.007 0.26 to 2.49 2.76 (0.29) 1.13 0.043 0.02 to 2.49
Family life 0.70 (0.24) 1.71 (0.24) 1.01 0.018 1.10 to 1.91 1.38 (0.24) 0.68 0.253 -0.21 to 1.57 1.46 (0.23) 0.76 0.138 -0.12 to 1.64
SF-36
Mental life 3.30 (1.13) 8.77 (1.12) 5.53 0.003 1.31 to 9.74 10.01 (1.11) 6.78 <0.001 2.58 to 10.98 6.60 (1.10) 3.37 0.197 -0.80 to 7.54